Infusion-related reaction to ramucirumab plus FOLFIRI in patients with advanced colorectal cancer

被引：0
|
作者：
Hiroyuki Okuyama
Yoshinori Kagawa
Toshiki Masuishi
Saori Mishima
Hiromichi Shirasu
Koji Ando
Satoshi Yuki
Kei Muro
Takayuki Yoshino
Kentaro Yamazaki
Eiji Oki
Yoshito Komatsu
Akihito Tsuji
机构：
[1] Kagawa University,Department of Clinical Oncology, Faculty of Medicine
[2] Kansai Rosai Hospital,Department of Colorectal Surgery
[3] Aichi Cancer Center Hospital,Department of Clinical Oncology
[4] National Cancer Center Hospital East,Department of Gastrointestinal Oncology
[5] Shizuoka Cancer Center,Division of Gastrointestinal Oncology
[6] Kyushu University,Department of Surgery and Science, Graduate School of Medical Sciences
[7] Hokkaido University Hospital,Department of Gastroenterology and Hepatology
[8] Hokkaido University Hospital Cancer Center,Department of Cancer Chemotherapy
来源：
International Journal of Clinical Oncology | 2021年 / 26卷
关键词：
Infusion reaction; Ramucirumab; Colorectal cancer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2025 / 2028
页数：3
相关论文
共 50 条
  • [31] Thrombotic events in patients with metastatic colorectal cancer treated with FOLFIRI plus bevacizumab
    Al-Shamsi, Humaid O.
    Anjum, Mahraz
    Al Farsi, Abdulaziz
    Shen, Hua
    Linkins, Lori-Ann
    Cook, Richard J.
    Major, Pierre
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [32] CetuximabInterstitial pneumonia and infusion-related reaction: 2 case reports
    Reactions Weekly, 2021, 1845 (1) : 127 - 127
  • [33] A toxicity comparison of FOLFIRI regimen (bimonthly irinotecan plus flurouracil/leucovorin) in elderly and younger patients with advanced colorectal cancer
    Satta, F.
    Todi, F.
    Zoffoli, M., V
    Burattini, E.
    Coiro, G.
    Pavese, I
    Di Palma, M.
    ANNALS OF ONCOLOGY, 2006, 17 : XI46 - XI46
  • [34] The Efficacy of FOLFIRI Plus Ramucirumab in Recurrent Colorectal Cancer Refractory to Adjuvant Chemotherapy with Oxaliplatin/Fluoropyrimidine-Including Biomarker Analyses
    Sugimoto, Naotoshi
    Noura, Shingo
    Kato, Takeshi
    Yoshioka, Shinichi
    Hata, Taishi
    Naito, Atsushi
    Tei, Mitsuyoshi
    Tamagawa, Hiroshi
    Komori, Takamichi
    Ide, Yoshihito
    Fukuzaki, Takayuki
    Danno, Katsuki
    Sawada, Genta
    Kagawa, Yoshinori
    Shimokawa, Toshio
    Miyoshi, Norikatsu
    Ogino, Takayuki
    Uemura, Mamoru
    Yamamoto, Hirofumi
    Murata, Kohei
    Doki, Yuichiro
    Eguchi, Hidetoshi
    CANCERS, 2025, 17 (01)
  • [35] Efficacy of ramucirumab in combination with second-line or salvage-line FOLFIRI in patients with metastatic colorectal cancer
    Katata, Y.
    Nagasaka, T.
    Tanioka, H.
    Nyuya, A.
    Toshima, T.
    Mori, Y.
    Shigeyasu, K.
    Okawaki, M.
    Yamamura, M.
    Tsuruta, A.
    Ueno, T.
    Yamaguchi, Y.
    ANNALS OF ONCOLOGY, 2018, 29 : 33 - 33
  • [36] Agalsidase-αInfusion-related reaction in a child: case report
    Reactions Weekly, 2011, 1352 (1) : 6 - 6
  • [37] Phase II randomized study of Folfiri vs Folfiri plus Celecoxib in first line treatment of advanced colorectal cancer (ACRC)
    Maiello, E.
    Giuliani, F.
    Romito, S.
    Pezzella, G.
    Mallamaci, R.
    Di Renzo, G.
    Di Bisceglie, M.
    Gebbia, V.
    Lopez, M.
    Colucci, G.
    ANNALS OF ONCOLOGY, 2005, 16 : 148 - 148
  • [38] Phase II randomized study of FOLFIRI vs FOLFIRI plus celecoxib in first line treatment of advanced colorectal cancer (ACRC).
    Maiello, E
    Giuliani, F
    Romito, S
    Pezzella, G
    Mallamaci, R
    Di Renzo, N
    Di Bisceglie, M
    Gebbia, V
    Lopez, M
    Colucci, G
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 284S - 284S
  • [39] Atezolizumab/BevacizumabGrade 4 infusion-related reaction: case report
    Reactions Weekly, 2024, 2037 (1) : 67 - 67
  • [40] RituximabAnaphylaxis and infusion-related hypersensitivity reaction: 2 case reports
    Reactions Weekly, 2021, 1862 (1) : 432 - 432
12345